Literature DB >> 30919287

In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia.

Elisabetta Morini1, Antonino Catalano1, Antonino Lasco1, Nunziata Morabito1, Salvatore Benvenga2,3,4.   

Abstract

PURPOSE: In postmenopausal women under L-T4 therapy, which was subsequently accompanied by calcium carbonate (CC) supplementation taken 6-8 h after tablet L-T4, TSH levels were greater than prior to adding CC. Total cholesterolemia [CHOL], fasting glycemia [FG], systolic and diastolic blood pressure [SBP, DBP] were also greater than baseline. Our aim was to explore the effects of either liquid or softgel capsule L-T4, while maintaining CC ingestion 6-8 h, later on TSH levels, CHOL, FG, SBP, and DBP.
METHODS: We proposed to 50 hypothyroid postmenopausal women under tablet L-T4 therapy, to switch to either liquid or softgel capsule L-T4 at the same daily dose while maintaining CC ingestion 6-8 h later. Sixteen women accepted [group I; liquid (n = 9), capsule (n = 7)], while 34 continued tablet L-T4 [group II, (n = 34)].
RESULTS: After 3 months, in group I, TSH decreased significantly (1.23 ± 0.49 vs. 1.80 ± 0.37 mU/L, P < 0.01), as did FG (80.7 ± 7.9 vs. 83.4 ± 6.3 mg/dL, P < 0.05); CHOL, SBP, and DBP decreased, though insignificantly. In contrast, in group II, TSH, FG, CHOL, SBP increased insignificantly, and DBP increased borderline significantly (69.7 ± 9 vs. 66.3 ± 6.5, P < 0.10). Compared to baseline (before adding CC), in group I, TSH was significantly lower (P < 0.01) and the other indices similar; in group II, TSH, FG, and SBP were significantly higher (P < 0.05), DBP borderline significantly higher (P < 0.10) and CHOL insignificantly higher. Performance of liquid L-T4 and capsule L-T4 was similar.
CONCLUSION: Delaying CC ingestion even by 6-8 h after taking tablet L-T4 is not entirely satisfactory, unlike liquid or softgel L-T4.

Entities:  

Keywords:  Blood glucose; Blood pressure; Calcium carbonate; Hypothyroidism; Liquid L-thyroxine; Serum cholesterol

Mesh:

Substances:

Year:  2019        PMID: 30919287     DOI: 10.1007/s12020-019-01908-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  37 in total

1.  Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs.

Authors:  Roberto Vita; Flavia Di Bari; Salvatore Benvenga
Journal:  Expert Opin Drug Deliv       Date:  2017-02-13       Impact factor: 6.648

2.  Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari; Roberto Vita
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

3.  Thyrotropin Levels, Insulin Resistance, and Metabolic Syndrome: A Cross-Sectional Analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

Authors:  Isabela M Benseñor; Alessandra Carvalho Goulart; Maria del Carmen B Molina; Érique José Peixoto de Miranda; Itamar S Santos; Paulo A Lotufo
Journal:  Metab Syndr Relat Disord       Date:  2015-07-15       Impact factor: 1.894

Review 4.  Gastrointestinal Malabsorption of Thyroxine.

Authors:  Camilla Virili; Alessandro Antonelli; Maria Giulia Santaguida; Salvatore Benvenga; Marco Centanni
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

5.  Association between thyrotropin levels and insulin sensitivity in euthyroid obese adolescents.

Authors:  Asma Javed; P Babu Balagopal; Adrian Vella; Philip R Fischer; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Paula D Giesler; Jeanette M Laugen; Seema Kumar
Journal:  Thyroid       Date:  2015-04-07       Impact factor: 6.568

6.  Relationship between serum TSH levels and intrarenal hemodynamic parameters in euthyroid subjects.

Authors:  Akihiro Tsuda; Masaaki Inaba; Mitsuru Ichii; Akinobu Ochi; Yoshiteru Ohno; Shinya Nakatani; Shinsuke Yamada; Katsuhito Mori; Hideki Tahara; Eiji Ishimura
Journal:  Eur J Endocrinol       Date:  2013-06-01       Impact factor: 6.664

7.  Thyroid function and blood pressure homeostasis in euthyroid subjects.

Authors:  Olga Gumieniak; Todd S Perlstein; Paul N Hopkins; Nancy J Brown; Laine J Murphey; Xavier Jeunemaitre; Norman K Hollenberg; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

Review 8.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

9.  Lower-normal TSH is associated with better metabolic risk factors: A cross-sectional study on Spanish men.

Authors:  M Laclaustra; Y Hurtado-Roca; M Sendin; M Leon; M Ledesma; E Andres; A Fernandez-Ortiz; E Guallar; J M Ordovas; J A Casasnovas
Journal:  Nutr Metab Cardiovasc Dis       Date:  2015-09-25       Impact factor: 4.222

10.  Relationship between high normal TSH levels and metabolic syndrome components in type 2 diabetic subjects with euthyroidism.

Authors:  Lilit Petrosyan
Journal:  J Clin Transl Endocrinol       Date:  2015-02-26
View more
  5 in total

Review 1.  Novel thyroxine formulations: a further step toward precision medicine.

Authors:  Camilla Virili; Pierpaolo Trimboli; Marco Centanni
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

Review 2.  Pharmacokinetics and Clinical Implications of Two Non-Tablet Oral Formulations of L-Thyroxine in Patients with Hypothyroidism.

Authors:  Pierpaolo Trimboli; Stéphane Mouly
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 3.  Fish and the Thyroid: A Janus Bifrons Relationship Caused by Pollutants and the Omega-3 Polyunsaturated Fatty Acids.

Authors:  Salvatore Benvenga; Fausto Famà; Laura Giovanna Perdichizzi; Alessandro Antonelli; Gabriela Brenta; Francesco Vermiglio; Mariacarla Moleti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

Review 4.  L-T4 Therapy in the Presence of Pharmacological Interferents.

Authors:  Salvatore Benvenga
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-22       Impact factor: 5.555

Review 5.  Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults.

Authors:  Philippe Caron; Solange Grunenwald; Luca Persani; Françoise Borson-Chazot; Remy Leroy; Leonidas Duntas
Journal:  Rev Endocr Metab Disord       Date:  2021-10-20       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.